Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Recap: European Affairs and Hematology at EHA2024

As at previous congresses, the European Affairs track at EHA2024 offered opportunities to learn, exchange, and connect.

Meet YoungEHA leaders Verena and Heiko

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee.

Wide Consensus Reached at Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine'

DUBLIN, March 25: Wide consensus emerged at the Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine’ on the need for radical change if Europe's approach to healthcare is to benefit from the potential of personalised medicine.

For mentors of applicants

As part of your support for the candidate applying for CBTH, the following is required from you:

Supervision and mentorship to be provided to the applicant during the CBTH award year.

EHA Statement on COVID-19 Vaccines

EHA-SHRC Hematology Tutorial on Thalassemia

Dates: May 10-11, 2018
Location: Shiraz, Iran
Chairs: M Karimi, MD Cappellini & A Taher

  

EHA in close collaboration with Shiraz Hematology Research Center and the Shiraz Medical Center, endorsed by the Iranian Pediatric Hematology Oncology Society, organize a two day tutorial on “Thalassemia”.…

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

New HemaSphere publication on IVDR implementation

The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU, has a major impact on commercially available IVDs (CEIVDs) and…